Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
351 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Schizophrenia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Schizophrenia - Pipeline Review, H2 2014', provides an overview of the Schizophrenia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Schizophrenia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 6 Schizophrenia Overview 7 Therapeutics Development 8 Schizophrenia - Therapeutics under Development by Companies 10 Schizophrenia - Therapeutics under Investigation by Universities/Institutes 17 Schizophrenia - Pipeline Products Glance 18 Schizophrenia - Products under Development by Companies 22 Schizophrenia - Products under Investigation by Universities/Institutes 31 Schizophrenia - Companies Involved in Therapeutics Development 32 Schizophrenia - Therapeutics Assessment 112 Drug Profiles 126 Schizophrenia - Recent Pipeline Updates 282 Schizophrenia - Dormant Projects 319 Schizophrenia - Discontinued Products 323 Schizophrenia - Product Development Milestones 325 Appendix 335
List of Tables Number of Products under Development for Schizophrenia, H2 2014 23 Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2014 24 Number of Products under Development by Companies, H2 2014 26 Number of Products under Development by Companies, H2 2014 (Contd..1) 27 Number of Products under Development by Companies, H2 2014 (Contd..2) 28 Number of Products under Development by Companies, H2 2014 (Contd..3) 29 Number of Products under Development by Companies, H2 2014 (Contd..4) 30 Number of Products under Development by Companies, H2 2014 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H2 2014 32 Comparative Analysis by Late Stage Development, H2 2014 33 Comparative Analysis by Clinical Stage Development, H2 2014 34 Comparative Analysis by Early Stage Development, H2 2014 35 Comparative Analysis by Unknown Stage Development, H2 2014 36 Products under Development by Companies, H2 2014 37 Products under Development by Companies, H2 2014 (Contd..1) 38 Products under Development by Companies, H2 2014 (Contd..2) 39 Products under Development by Companies, H2 2014 (Contd..3) 40 Products under Development by Companies, H2 2014 (Contd..4) 41 Products under Development by Companies, H2 2014 (Contd..5) 42 Products under Development by Companies, H2 2014 (Contd..6) 43 Products under Development by Companies, H2 2014 (Contd..7) 44 Products under Development by Companies, H2 2014 (Contd..8) 45 Products under Investigation by Universities/Institutes, H2 2014 46 Schizophrenia - Pipeline by AbbVie Inc., H2 2014 47 Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 48 Schizophrenia - Pipeline by Adamed Sp. z o.o., H2 2014 49 Schizophrenia - Pipeline by Addex Therapeutics Ltd, H2 2014 50 Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H2 2014 51 Schizophrenia - Pipeline by AGY Therapeutics, Inc., H2 2014 52 Schizophrenia - Pipeline by Alkermes Plc, H2 2014 53 Schizophrenia - Pipeline by Amgen Inc., H2 2014 54 Schizophrenia - Pipeline by Angita B.V., H2 2014 55 Schizophrenia - Pipeline by Ascendis Pharma A/S, H2 2014 56 Schizophrenia - Pipeline by Astellas Pharma Inc., H2 2014 57 Schizophrenia - Pipeline by Athersys, Inc., H2 2014 58 Schizophrenia - Pipeline by BioCrea GmbH, H2 2014 59 Schizophrenia - Pipeline by Biotie Therapies Corp., H2 2014 60 Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2014 61 Schizophrenia - Pipeline by BRAINco Biopharma, S.L., H2 2014 62 Schizophrenia - Pipeline by Cerecor Inc., H2 2014 63 Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H2 2014 64 Schizophrenia - Pipeline by Curemark, LLC, H2 2014 65 Schizophrenia - Pipeline by Delpor, Inc., H2 2014 66 Schizophrenia - Pipeline by Domain Therapeutics SA, H2 2014 67 Schizophrenia - Pipeline by Dong Wha Pharma Co., Ltd., H2 2014 68 Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H2 2014 69 Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H2 2014 70 Schizophrenia - Pipeline by Eli Lilly and Company, H2 2014 71 Schizophrenia - Pipeline by Evotec AG, H2 2014 72 Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 73 Schizophrenia - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 74 Schizophrenia - Pipeline by Galenea Corp., H2 2014 75 Schizophrenia - Pipeline by GeNeuro SA, H2 2014 76 Schizophrenia - Pipeline by Genovate Biotechnology Co., LTD., H2 2014 77 Schizophrenia - Pipeline by Gilead Sciences, Inc., H2 2014 78 Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 79 Schizophrenia - Pipeline by GP Pharm, S.A., H2 2014 80 Schizophrenia - Pipeline by GW Pharmaceuticals plc, H2 2014 81 Schizophrenia - Pipeline by H. Lundbeck A/S, H2 2014 82 Schizophrenia - Pipeline by Heptares Therapeutics Ltd., H2 2014 83 Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2014 84 Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 85 Schizophrenia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2014 86 Schizophrenia - Pipeline by Jiangsu Nhwa Pharma Corporation, H2 2014 87 Schizophrenia - Pipeline by Johnson & Johnson, H2 2014 88 Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H2 2014 89 Schizophrenia - Pipeline by KemPharm, Inc., H2 2014 90 Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2014 91 Schizophrenia - Pipeline by Lead Discovery Center GmbH, H2 2014 92 Schizophrenia - Pipeline by Luye Pharma Group Ltd., H2 2014 93 Schizophrenia - Pipeline by MarcoPolo Pharmaceuticals SA, H2 2014 94 Schizophrenia - Pipeline by Merck & Co., Inc., H2 2014 95 Schizophrenia - Pipeline by Mithridion, Inc., H2 2014 96 Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 97 Schizophrenia - Pipeline by Naurex, Inc., H2 2014 98 Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H2 2014 99 Schizophrenia - Pipeline by NeurOp, Inc, H2 2014 100 Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 101 Schizophrenia - Pipeline by Novartis AG, H2 2014 102 Schizophrenia - Pipeline by Nuvo Research Inc., H2 2014 103 Schizophrenia - Pipeline by Omeros Corporation, H2 2014 104 Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 105 Schizophrenia - Pipeline by Peptron, Inc., H2 2014 106 Schizophrenia - Pipeline by Pfizer Inc., H2 2014 107 Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H2 2014 108 Schizophrenia - Pipeline by Reckitt Benckiser Pharmaceutical, Inc., H2 2014 109 Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 110 Schizophrenia - Pipeline by Richter Gedeon Nyrt., H2 2014 111 Schizophrenia - Pipeline by Rottapharm SpA, H2 2014 112 Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 113 Schizophrenia - Pipeline by SK Chemicals Co., Ltd., H2 2014 114 Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 115 Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 116 Schizophrenia - Pipeline by Suven Life Sciences Ltd., H2 2014 117 Schizophrenia - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 118 Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 119 Schizophrenia - Pipeline by Targacept, Inc., H2 2014 120 Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H2 2014 121 Schizophrenia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 122 Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H2 2014 123 Schizophrenia - Pipeline by XTL Biopharmaceuticals Ltd., H2 2014 124 Schizophrenia - Pipeline by Zogenix, Inc., H2 2014 125 Schizophrenia - Pipeline by Zysis Limited, H2 2014 126 Assessment by Monotherapy Products, H2 2014 127 Assessment by Combination Products, H2 2014 128 Number of Products by Stage and Target, H2 2014 130 Number of Products by Stage and Mechanism of Action, H2 2014 134 Number of Products by Stage and Route of Administration, H2 2014 138 Number of Products by Stage and Molecule Type, H2 2014 140 Schizophrenia Therapeutics - Recent Pipeline Updates, H2 2014 297 Schizophrenia - Dormant Projects, H2 2014 334 Schizophrenia - Discontinued Products, H2 2014 338
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
